Daunorubicin+cytarabine

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, First Affiliated Hospital of Zhejiang University

Conditions

AMLAcute Myeloid LeukemiaLisaftoclax

Phase 2

Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

Enrolling by invitationNCT07651176

First Affiliated Hospital of Zhejiang UniversityAcute Myeloid Leukemia, Lisaftoclax

Start: 2026-03-01End: 2029-12-01Target: 267Updated: 2026-06-16

Unknown Phase

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

RecruitingNCT06529250

Institute of Hematology & Blood Diseases Hospital, ChinaAML

Start: 2024-08-13End: 2028-09-01Target: 148Updated: 2025-01-16